{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:04:07Z","timestamp":1775556247456,"version":"3.50.1"},"reference-count":27,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>\n          <jats:bold>OBJECTIVES<\/jats:bold> Limited data exist regarding clinical outcomes of invasive methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) infections in children treated with vancomycin. Treatment success in adults correlates best with an area under the curve\/minimum inhibitory concentration (AUC<jats:sub>24<\/jats:sub>\/MIC) ratio \u2265400. It is unknown if this relationship is useful in children.<\/jats:p>\n        <jats:p>\n          <jats:bold>METHODS<\/jats:bold> Charts of children who received vancomycin \u22655 days for MRSA bacteremia with a steady state trough were reviewed. AUC<jats:sub>24<\/jats:sub>\/MIC ratios were estimated using 2 different vancomycin clearance equations. Vancomycin treatment failure was defined as persistent bacteremia \u22657 days, recurrent bacteremia within 30 days, or 30-day mortality.<\/jats:p>\n        <jats:p>\n          <jats:bold>RESULTS<\/jats:bold> There were 67 bacteremia episodes in 65 patients. Nine (13.4%) met failure criteria: persistent bacteremia (n = 6), recurrent bacteremia (n = 2), 30-day mortality (n = 1). There were no differences between patients receiving &lt;60 mg\/kg\/day and \u226560 mg\/kg\/day of vancomycin in median trough (11.9 versus 12.3 mg\/L, p = 0.1). Troughs did not correlate well with AUC<jats:sub>24<\/jats:sub>\/MIC ratios (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup> = 0.32 and 0.22). Patients receiving \u226560 mg\/kg\/day had greater probability of achieving ratios \u2265400. There were no significant differences in median dose (p = 0.8), trough (p = 0.24), or AUC<jats:sub>24<\/jats:sub>\/MIC ratios (p = 0.07 and p = 0.6) between patients with treatment success and failure.<\/jats:p>\n        <jats:p>\n          <jats:bold>CONCLUSIONS<\/jats:bold> Treatment failure was lower than previously reported in children. AUC<jats:sub>24<\/jats:sub>\/MIC ratios \u2265400 were frequently achieved but were not associated with treatment success, dose, or troughs. Prospective studies using standard definitions of vancomycin treatment failure are needed to understand treatment failure in children with MRSA bacteremia.<\/jats:p>","DOI":"10.5863\/1551-6776-24.4.312","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T20:39:48Z","timestamp":1563223188000},"page":"312-319","source":"Crossref","is-referenced-by-count":1,"title":["Vancomycin Treatment Failure in Children With Methicillin-Resistant Staphylococcus aureus Bacteremia"],"prefix":"10.5863","volume":"24","author":[{"given":"Rebecca B.","family":"Regen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah S.","family":"Schuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca F.","family":"Chhim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra R.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"5","key":"i1551-6776-24-4-312-b1","series-title":"Ther Drug Monit","first-page":"619","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"37","year":"2015","unstructured":"Hahn\n              A\n            , FrenckRW, Allen-StaatM, \n          et al. Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia. Ther Drug Monit. 2015;37(5):619\u2013625."},{"issue":"3","key":"i1551-6776-24-4-312-b2","series-title":"J Clin Microbiol","first-page":"894","article-title":"Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin","volume":"48","year":"2010","unstructured":"Welsh\n              KJ\n            , AbbottAN, LewisEM, \n          et al. Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin. J Clin Microbiol. 2010;48(3):894\u2013899."},{"issue":"3","key":"i1551-6776-24-4-312-b3","series-title":"J Pediatric Infect Dis Soc","first-page":"259","article-title":"Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive Staphylococcal infections","volume":"2","year":"2013","unstructured":"Chhim\n              RF\n            , ArnoldSR, LeeKR.\n          Vancomycin dosing practices, trough concentrations, and predicted area under the curve in children with suspected invasive Staphylococcal infections. J Pediatric Infect Dis Soc. 2013;2(3):259\u2013262."},{"issue":"6","key":"i1551-6776-24-4-312-b4","series-title":"Pediatrics","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"139","year":"2017","unstructured":"Hamdy\n              RF\n            , HsuAJ, StockmanC, \n          et al. Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children. Pediatrics. 2017;139(6):e20170183."},{"issue":"00","key":"i1551-6776-24-4-312-b5","series-title":"J Pediatric Infect Dis Soc","first-page":"1","article-title":"Association between vancomycin trough concentrations and duration of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"00","year":"2017","unstructured":"Hsu\n              AJ\n            , HamdyRF, HuangY, \n          et al. Association between vancomycin trough concentrations and duration of methicillin-resistant Staphylococcus aureus bacteremia in children. J Pediatric Infect Dis Soc. 2017:00(00):1\u20134."},{"issue":"1","key":"i1551-6776-24-4-312-b6","series-title":"J Pediatr Pharmacol Ther","first-page":"41","article-title":"Vancomycin AUC\/MIC and corresponding troughs in a pediatric population","volume":"22","year":"2017","unstructured":"Kishk\n              OA\n            , LardieriAB, HeilEL, \n          et al. Vancomycin AUC\/MIC and corresponding troughs in a pediatric population. J Pediatr Pharmacol Ther. 2017;22(1):41\u201347."},{"issue":"3","key":"i1551-6776-24-4-312-b7","series-title":"Pediatr Infect Dis J","first-page":"263","article-title":"Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome","volume":"35","year":"2016","unstructured":"McNeil\n              JC\n            , KokEY, ForbesAR, \n          et al. Healthcare-associated Staphylococcus aureus bacteremia in children: evidence for reverse vancomycin creep and impact of vancomycin trough values on outcome. Pediatr Infect Dis J. 2016;35(3):263\u2013268."},{"issue":"13","key":"i1551-6776-24-4-312-b8","series-title":"Clin Pharmacokinet","first-page":"925","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","year":"2004","unstructured":"Moise-Broder\n              PA\n            , ForrestA, BirminghamMC, \n          et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925\u2013942."},{"issue":"2","key":"i1551-6776-24-4-312-b9","series-title":"Antimicrob Agents Chemother","first-page":"634","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistantStaphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","year":"2012","unstructured":"Brown\n              J\n            , BrownK, ForrestA.\n          Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistantStaphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother. 2012;56(2):634\u2013638."},{"issue":"6","key":"i1551-6776-24-4-312-b10","series-title":"Clin Ther","first-page":"772","article-title":"A stewardship program's retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis","volume":"35","year":"2013","unstructured":"Gawronski\n              KM\n            , GoffDA, BrownJ, \n          et al. A stewardship program's retrospective evaluation of vancomycin AUC24\/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. Clin Ther. 2013;35(6):772\u2013779."},{"issue":"3","key":"i1551-6776-24-4-312-b11","series-title":"Clin Infect Dis","first-page":"285","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","year":"2011","unstructured":"Liu\n              C\n            , BayerA, CosgroveSE, \n          et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285\u2013292."},{"issue":"11","key":"i1551-6776-24-4-312-b12","series-title":"Pharmacotherapy","first-page":"1275","article-title":"Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"29","year":"2009","unstructured":"Rybak\n              MJ\n            , LomaestroBM, RotschaferJC, \n          et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(11):1275\u20131279."},{"issue":"10","key":"i1551-6776-24-4-312-b13","series-title":"Pediatr Infect Dis J","first-page":"1077","article-title":"Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections","volume":"32","year":"2013","unstructured":"Frymoyer\n              A\n            , GuglielmoBJ, HershAL.\n          Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077\u20131079."},{"issue":"4","key":"i1551-6776-24-4-312-b14","series-title":"Pediatr Infect Dis J","first-page":"e155","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","year":"2013","unstructured":"Le\n              J\n            , BradleyJS, MurrayW, \n          et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155\u2013e163."},{"key":"i1551-6776-24-4-312-b15","series-title":"Pediatr Infect Dis J","first-page":"e244","article-title":"Correlation of a vancomycin pharmacokinetic model and trough serum concentrations in pediatric patients","volume":"34","year":"2015","unstructured":"Ploessel\n              C\n            , WhiteC, ManascoK.\n          Correlation of a vancomycin pharmacokinetic model and trough serum concentrations in pediatric patients. Pediatr Infect Dis J. 2015;34:e244\u2013e247."},{"issue":"1","key":"i1551-6776-24-4-312-b16","series-title":"J Clin Pharmacol","first-page":"77","article-title":"AUC-guided vancomycin in adolescent patients with suspected sepsis","volume":"57","year":"2017","unstructured":"Lanke\n              S\n            , YuT, RowerJE, \n          et al. AUC-guided vancomycin in adolescent patients with suspected sepsis. J Clin Pharmacol. 2017;57(1):77\u201384."},{"issue":"4","key":"i1551-6776-24-4-312-b17","series-title":"J Microbiol Immunol Infect","first-page":"494","article-title":"Vancomycin dosing and target attainment in children","volume":"50","year":"2017","unstructured":"Hwang\n              D\n            , ChiuN, ChangL, \n          et al. Vancomycin dosing and target attainment in children. J Microbiol Immunol Infect. 2017;50(4):494\u2013499."},{"issue":"8","key":"i1551-6776-24-4-312-b18","series-title":"Pediatric Infect Dis J","first-page":"667","article-title":"Influence of malignancy on the pharmacokinetics of vancomycin in infants and children","volume":"14","year":"1995","unstructured":"Chang\n              D.\n            \n          \n          Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatric Infect Dis J. 1995;14(8):667\u2013673."},{"issue":"6","key":"i1551-6776-24-4-312-b19","series-title":"J Pediatr","first-page":"849","article-title":"A simple estimate of glomerular filtration rate in full-term infants during the first year of life","volume":"104","year":"1984","unstructured":"Schwartz\n              GJ\n            , FeldLG, LangfordDJ.\n          A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984;104(6):849\u2013854."},{"issue":"11","key":"i1551-6776-24-4-312-b20","series-title":"J Am Soc Nephrol","first-page":"1832","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","year":"2009","unstructured":"Schwartz\n              GJ\n            , WorkDF.\n          Measurement and estimation of GFR in children and adolescents. J Am Soc Nephrol. 2009;4(11):1832\u2013643."},{"issue":"3","key":"i1551-6776-24-4-312-b21","series-title":"Pediatr Clin North Am","first-page":"571","article-title":"The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents","volume":"34","year":"1987","unstructured":"Schwartz\n              GJ\n            , BrionLP, SpitzerA.\n          The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34(3):571\u2013590"},{"key":"i1551-6776-24-4-312-b22","series-title":"J Korean Med Sci","first-page":"22","article-title":"Impact of initial vancomycin trough concentration on clinical and micrological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"32","year":"2017","unstructured":"Yoo\n              RN\n            , KimSH, LeeJ.\n          Impact of initial vancomycin trough concentration on clinical and micrological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children. J Korean Med Sci. 2017;32:22\u201328."},{"issue":"9","key":"i1551-6776-24-4-312-b23","series-title":"Antimicrob Agents Chemother","first-page":"3315","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","year":"2008","unstructured":"Lodise\n              TP\n            , GravesJ, EvansA, \n          et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315\u20133320."},{"issue":"3","key":"i1551-6776-24-4-312-b24","series-title":"Pharmacotherapy","first-page":"195","article-title":"Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort","volume":"32","year":"2012","unstructured":"Kullar\n              R\n            , DavisSL, TaylorTN, \n          et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012;32(3):195\u2013201."},{"issue":"8","key":"i1551-6776-24-4-312-b25","series-title":"Clin Infect Dis","first-page":"975","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","year":"2011","unstructured":"Kullar\n              R\n            , DavisSL, LevineDP, \n          et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52(8):975\u2013981."},{"issue":"9","key":"i1551-6776-24-4-312-b26","series-title":"Pharmacotherapy","first-page":"871","article-title":"Impact of a hospital-wide increase in empiric pediatric vancomycin dosing on initial trough concentrations","volume":"31","year":"2011","unstructured":"Frymoyer\n              A\n            , GuglielmoBJ, WilsonSD, \n          et al. Impact of a hospital-wide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy. 2011;31(9):871\u2013876."},{"issue":"5","key":"i1551-6776-24-4-312-b27","series-title":"Ann Pharmacother","first-page":"582","article-title":"Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients","volume":"45","year":"2011","unstructured":"Eiland\n              LS\n            , EnglishTM, EilandEH.\n          Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45(5):582\u2013589."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/4\/article-p312.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/24\/4\/312\/2468219\/1551-6776-24_4_312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/4\/article-p312.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/24\/4\/article-p312.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:43:34Z","timestamp":1747356214000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/24\/4\/article-p312.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":27,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-24.4.312","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}